GPT and metabolic dysfunction-associated steatotic liver disease: A previous study conducted in Japan showed that treatment with pemafibrate significantly improved levels of alanine aminotransferase (ALT), γ-GTP and alkaline phosphatase (ALP) in patients with NAFLD compared with placebo (18).